Literature DB >> 11838793

Predictors of vestibular schwannoma growth in patients with neurofibromatosis Type 2.

Michael E Baser1, Erini V Makariou, Dilys M Parry.   

Abstract

OBJECT: The results of two longitudinal studies of growth rates of vestibular schwannomas (VSs) in patients with neurofibromatosis Type 2 (NF2) differ as to whether VS growth rates decrease or increase with increasing patient age. The authors undertook this study to assess the relationship between VS growth rates and patient age and type of constitutional NF2 mutation; they also examined variability in VS growth rates among multiple patients in families with NF2.
METHODS: Gadolinium-enhanced magnetic resonance images obtained in 18 patients with inherited NF2 from 11 unrelated families were retrospectively analyzed. The patients had been observed for a median of 4 years. Volumes of the VSs were measured using a two-component box model (intrameatal and extrameatal parts measured separately). Single-strand conformation polymorphism analysis and Southern blot analysis were used to identify constitutional NF2 mutations. Growth rates of the VSs were highly variable, but tended to decrease with increasing patient age both at onset of signs or symptoms of NF2 (r2 = 0.35, p = 0.026) and at diagnosis (r2 = 0.33, p = 0.012). The VS growth rates did not vary significantly with the type of constitutional NF2 mutation or the number of non-VS cerebral or spinal tumors. The VS growth rates were highly variable within families and did not correspond to clinical indices of NF2 disease severity, such as patient age at symptom onset and the number of non-VS cerebral and spinal tumors.
CONCLUSIONS: The growth rates of VSs in patients with NF2 are highly variable, but tend to decrease with increasing patient age. Clinical treatment of multiple patients in families with NF2 cannot be based on the expectations of similar VS growth rates, even when other clinical aspects of disease severity are similar.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11838793     DOI: 10.3171/jns.2002.96.2.0217

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  22 in total

Review 1.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

Review 2.  The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2.

Authors:  M E Baser; L Kuramoto; R Woods; H Joe; J M Friedman; A J Wallace; R T Ramsden; S Olschwang; E Bijlsma; M Kalamarides; L Papi; R Kato; J Carroll; C Lázaro; F Joncourt; D M Parry; G A Rouleau; D G R Evans
Journal:  J Med Genet       Date:  2005-07       Impact factor: 6.318

3.  Determination of the clinical growth index in unilateral vestibular schwannoma.

Authors:  Marc Diensthuber; Thomas Lenarz; Timo Stöver
Journal:  Skull Base       Date:  2006-02

Review 4.  Methodological issues in longitudinal studies: vestibular schwannoma growth rates in neurofibromatosis 2.

Authors:  M E Baser; V-F Mautner; D M Parry; D G R Evans
Journal:  J Med Genet       Date:  2005-04-14       Impact factor: 6.318

5.  Surgical treatment of large vestibular schwannomas in patients with neurofibromatosis type 2: outcomes on facial nerve function and hearing preservation.

Authors:  Fu Zhao; Bo Wang; Zhijun Yang; Qiangyi Zhou; Peng Li; Xingchao Wang; Jing Zhang; Junting Zhang; Pinan Liu
Journal:  J Neurooncol       Date:  2018-02-28       Impact factor: 4.130

6.  Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors.

Authors:  Michael S Dirks; John A Butman; H Jeffrey Kim; Tianxia Wu; Keaton Morgan; Anne P Tran; Russell R Lonser; Ashok R Asthagiri
Journal:  J Neurosurg       Date:  2012-04-13       Impact factor: 5.115

7.  Increased growth rate of vestibular schwannoma after resection of contralateral tumor in neurofibromatosis type 2.

Authors:  Matthieu Peyre; Stephane Goutagny; Sandrine Imbeaud; Alexis Bozorg-Grayeli; Michele Felce; Olivier Sterkers; Michel Kalamarides
Journal:  Neuro Oncol       Date:  2011-07-28       Impact factor: 12.300

8.  Predictors of the risk of mortality in neurofibromatosis 2.

Authors:  Michael E Baser; J M Friedman; Dana Aeschliman; Harry Joe; Andrew J Wallace; Richard T Ramsden; D Gareth R Evans
Journal:  Am J Hum Genet       Date:  2002-08-22       Impact factor: 11.025

9.  Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study.

Authors:  Michael E Baser; Lisa Kuramoto; Harry Joe; J M Friedman; Andrew J Wallace; James E Gillespie; Richard T Ramsden; D Gareth R Evans
Journal:  Am J Hum Genet       Date:  2004-06-09       Impact factor: 11.025

Review 10.  Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.

Authors:  Scott R Plotkin; Chris Halpin; Jaishri O Blakeley; William H Slattery; D Bradley Welling; Susan M Chang; Jay S Loeffler; Gordon J Harris; A Gregory Sorensen; Michael J McKenna; Fred G Barker
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.